# A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).

> **NCT00383019** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 300 (actual)

## Conditions studied

- Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Xalatan
- **DRUG:** Xalacom

## Key facts

- **NCT ID:** NCT00383019
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-14
- **Primary completion:** 2007-10-01
- **Final completion:** 2007-10-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2021-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383019, "A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00383019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*